Navigation Links
Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
Date:3/2/2011

EAST BRUNSWICK, N.J., March 2, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the 31st Annual Cowen & Co. Health Care Conference, on Monday, March 7, 2011, at 1:00 p.m. Eastern Time.  The conference will be held at The Boston Marriott Copley Place in Boston, MA.  

A live webcast of the presentation can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
2. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
3. Savient Closes Sale of $230 Million in Convertible Senior Notes
4. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
5. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
6. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
7. Savient Pharmaceuticals Announces Search for CEO
8. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
10. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
11. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/4/2017)... Md. , Aug. 4, 2017 The ... or shortly after a physician/patient consult has long been ... and was a notable focus of the largest meeting ... is according to healthcare market research firm Kalorama Information. ... care testing (POCT) offerings or related supplies and software ...
(Date:8/2/2017)... Tenn. and BENTON, Ky. , Aug. 2, 2017   ... member to its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections ... a UV disinfection robot that uses UVC light energy to kill deadly pathogens such as ... ... Tru-D in ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... This week the The Voss ... Texas. Founded by Bill Voss, the firm grew quickly and has built a reputation ... of helping clients get the money they deserve from their insurance companies. , ...
(Date:8/23/2017)... ... August 23, 2017 , ... Based on ... safety and efficacy of HBOT in treating and helping to heal addictions and ... research showing the similarities of the wounds to the brain from traumatic brain ...
(Date:8/23/2017)... ... 23, 2017 , ... PreCheck, Inc., a background screening and ... with a three-year sales growth of 49 percent . The Inc. 5000 is ... comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s fifth consecutive entry on ...
(Date:8/23/2017)... ... August 23, 2017 , ... MobilityWorks ®, the ... to the 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. ... 139 percent, marking the twelfth year that the company has been included on ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... American Academy of Orthopaedic Surgeons , points out that therapeutic modalities (physical ... pain or injury. According to the report, a wider scope of physical therapy ...
Breaking Medicine News(10 mins):